title: Imagine a world without cancer.
abstract: BACKGROUND
  Since the "War on Cancer" was declared in 1971, the United States alone has expended some $300 billion on research, with a heavy focus on the role of genomics in anticancer therapy. Voluminous data have been collected and analyzed. However, in hindsight, any achievements made have not been realized in clinical practice in terms of overall survival or quality of life extended. This might be justified because cancer is not one disease but a conglomeration of multiple diseases, with widespread heterogeneity even within a single tumor type.
  
  
  CONCLUSIONS
  Only a few types of cancer have been described that are associated with one major signaling pathway. This enabled the initial successful deployment of targeted therapy for such cancers. However, soon after this targeted approach was initiated, it was subverted as cancer cells learned and reacted to the initial treatments, oftentimes rendering the treatment less effective or even completely ineffective. During the past 30 plus years, the cancer classification used had, as its primary aim, the facilitation of communication and the exchange of information amongst those caring for cancer patients with the end goal of establishing a standardized approach for the diagnosis and treatment of cancers. This approach should be modified based on the recent research to affect a change from a service-based to an outcome-based approach. The vision of achieving long-term control and/or eradicating or curing cancer is far from being realized, but not impossible. In order to meet the challenges in getting there, any newly proposed anticancer strategy must integrate a personalized treatment outcome approach. This concept is predicated on tumor- and patient-associated variables, combined with an individualized response assessment strategy for therapy modification as suggested by the patient's own results. As combined strategies may be outcome-orientated and integrate tumor-, patient- as well as cancer-preventive variables, this approach is likely to result in an optimized anticancer strategy.
  
  
  CONCLUSIONS
  Herein, we introduce such an anticancer strategy for all cancer patients, experts, and organizations: Imagine a World without Cancer.
authors.affiliation: Theodor-Billroth-Academy®, Munich, Germany. b-bruecher@gmx.de.
authors.forename: Björn L D M
authors.initials: BL
authors.lastname: Brücher
authors.forename: Gary
authors.initials: G
authors.lastname: Lyman
authors.forename: Richard
authors.initials: R
authors.lastname: van Hillegersberg
authors.forename: Raphael E
authors.initials: RE
authors.lastname: Pollock
authors.forename: Florian
authors.initials: F
authors.lastname: Lordick
authors.forename: Han-Kwang
authors.initials: HK
authors.lastname: Yang
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Ushijima
authors.forename: Khay-Guan
authors.initials: KG
authors.lastname: Yeoh
authors.forename: Tomas
authors.initials: T
authors.lastname: Skricka
authors.forename: Wojciech
authors.initials: W
authors.lastname: Polkowski
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Wallner
authors.forename: Vic
authors.initials: V
authors.lastname: Verwaal
authors.forename: Alfredo
authors.initials: A
authors.lastname: Garofalo
authors.forename: Domenico
authors.initials: D
authors.lastname: D'Ugo
authors.forename: Franco
authors.initials: F
authors.lastname: Roviello
authors.forename: Hans-Ulrich
authors.initials: HU
authors.lastname: Steinau
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Wallace
authors.forename: Martin
authors.initials: M
authors.lastname: Daumer
authors.forename: Nitah
authors.initials: N
authors.lastname: Maihle
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Reid
authors.forename: Michel
authors.initials: M
authors.lastname: Ducreux
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Alexander
authors.initials: A
authors.lastname: Knuth
authors.forename: Bruno
authors.initials: B
authors.lastname: Zilberstein
authors.forename: Scott R
authors.initials: SR
authors.lastname: Steele
authors.forename: Ijaz S
authors.initials: IS
authors.lastname: Jamall
mesh_terms: D024221:Antineoplastic Protocols; D003131:Combined Modality Therapy; D055088:Early Detection of Cancer / Q000379:methods / Q000639:trends; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D057285:Precision Medicine / Q000379:methods / Q000639:trends